Journal of Medicine and Life Science

  • 제19권1호
  • /
  • Pages.14-19
  • /
  • 2022
  • /
  • 1738-1010(pISSN)
  • /
  • 2671-4922(eISSN)
제주대학교 의과학연구소 (Institute for Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease

  • Yang, Jieun (Department of Internal Medicine, Seoul National University Hospital) ;
  • park, Ji Eun (Department of Internal Medicine, Jeju National University Hospital) ;
  • Jo, Jaemin (Department of Internal Medicine, Jeju National University Hospital) ;
  • Kim, Young Ree (Jeju National University College of Medicine) ;
  • Chang, Jee Won (Jeju National University College of Medicine) ;
  • Han, Sang Hoon (Department of Internal Medicine, Jeju National University Hospital) ;
  • Han, Chi Wha (Department of Internal Medicine, Jeju National University Hospital)
  • 투고 : 2021.11.03
  • 심사 : 2022.03.30
  • 발행 : 2022.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We investigated the safety and efficacy of pemetrexed monotherapy in patients with lung adenocarcinoma and various renal conditions, including chronic kidney disease. We also analyzed whether baseline renal function affected progression-free survival (PFS). We retrospectively analyzed 71 patients who received maintenance-and second-line pemetrexed monotherapy. Patients were divided into two groups according to estimated glomerular filtration rate (eGFR): fair eGFR (>60 mL/min/1.73 m2) and lower eGFR (59 mL/min/1.73 m2 or less). The safety and efficacy were evaluated for each group. Median ages were 73.2 years in the lower eGFR group (n=28) and 64.5 years in the fair eGFR group (n=43). Patients with a lower eGFR achieved a median PFS of 4.7 months, while the median PFS for patients with a fair eGFR was 2.7 months. The difference between the two groups was not statistically significant (P=0.075). Both groups showed treatment-related low-grade hematological and non-hematological adverse events. Pemetrexed monotherapy is safe and effective in patients with lung adenocarcinoma with a lower eGFR.

키워드

참고문헌

  1. Kweon SS. Updates on cancer epidemiology in Korea, 2018. Chon-nam Med J 2018;54:90-100. https://doi.org/10.4068/cmj.2018.54.2.90
  2. Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience 2016;10:648.
  3. Pirker R. Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key. Ann Transl Med 2019;7(Suppl 1):S48. https://doi.org/10.21037/atm.2019.03.10
  4. Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, et al. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials. J Clin Oncol 2018;36:2585-92. https://doi.org/10.1200/JCO.2017.76.8390
  5. de Rouw N, Boosman RJ, van de Bruinhorst H, Biesma B, van den Heuvel MM, Burger DM, et al. Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 2020;146:30-5. https://doi.org/10.1016/j.lungcan.2020.05.022
  6. Hata A, Katakami N, Hattori Y, Tanaka K, Fujita S, Kotani Y, et al. Pemetrexed monotherapy for chemo-naive elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003). Cancer Chemother Pharmacol 2017;79:689-95. https://doi.org/10.1007/s00280-017-3259-z
  7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. https://doi.org/10.1200/JCO.2007.15.0375
  8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. https://doi.org/10.7326/0003-4819-130-6-199903160-00002
  9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
  10. Bluthgen MV, Besse B. Second-line combination therapies in non-small cell lung cancer without known driver mutations. Eur Respir Rev 2015;24:582-93. https://doi.org/10.1183/16000617.00002115
  11. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-62. https://doi.org/10.1200/JCO.2004.00.9720
  12. Levey AS, Inker LA. GFR as the "gold standard": estimated, measured, and true. Am J Kidney Dis 2016;67:9-12. https://doi.org/10.1053/j.ajkd.2015.09.014